| Literature DB >> 31333421 |
Amaury De Barros1,2, Germain Arribarat1, Jeanne Combis1, Patrick Chaynes2, Patrice Péran1.
Abstract
Iron levels in the brain can be estimated using newly developed specific magnetic resonance imaging (MRI) sequences. This technique has several applications, especially in neurodegenerative disorders like Alzheimer's disease or Parkinson's disease. Coupling ex vivo MRI with histology allows neuroscientists to better understand what they see in the images. Iron is one of the most extensively studied elements, both by MRI and using histological or physical techniques. Researchers were initially only able to make visual comparisons between MRI images and different types of iron staining, but the emergence of specific MRI sequences like R2* or quantitative susceptibility mapping meant that quantification became possible, requiring correlations with physical techniques. Today, with advances in MRI and image post-processing, it is possible to look for MRI/histology correlations by matching the two sorts of images. For the result to be acceptable, the choice of methodology is crucial, as there are hidden pitfalls every step of the way. In order to review the advantages and limitations of ex vivo MRI correlation with iron-based histology, we reviewed all the relevant articles dealing with the topic in humans. We provide separate assessments of qualitative and quantitative studies, and after summarizing the significant results, we emphasize all the pitfalls that may be encountered.Entities:
Keywords: QSM; ex vivo; iron histology; iron quantification; magnetic resonance imaging
Year: 2019 PMID: 31333421 PMCID: PMC6616088 DOI: 10.3389/fnana.2019.00068
Source DB: PubMed Journal: Front Neuroanat ISSN: 1662-5129 Impact factor: 3.856
Figure 1Perls' staining of right lenticular nucleus in coronal plane (a); Perls + DAB staining of right lenticular nucleus (b). both Perls and Perls + DAB were counterstained with nuclear fast red. Image obtained during experimental procedures with all appropriate ethical approval. Included for illustrative purposes.
Figure 2Flowchart depicting systematic review process.
List of all references featuring iron descriptions by both MRI and histological/physical technique.
| Chen et al., | T2 (1.5T) | Iron: Perls and AAS | Fresh brains | Control | 10 | Qualitative and quantitative |
| Dhenain et al., | T2* (11.7T) | Iron: Perls + DAB | Superior temporal gyrus / Senile plaques (fixed) | AD | 2 | Qualitative |
| Fujii et al., | T2 (3T) | Iron: PerlsFerritin: IHC | Putamen (fixed) | Control | 4 | Qualitative |
| House et al., | R2 (4.7T) | Iron: AAS | 10-mm coronal slices of thawed hemispheres | AD | 4 | Quantitative |
| House et al., | R1 (1.4T) | Iron: Perls and ICP-AES | 10-mm coronal slices of thawed hemispheres | AD | 3 | Quantitative (ICP-AES) |
| Matsusue et al., | T2 (1.5, 3T) | Iron: PerlsFerritin: IHC | Putamen (fixed) | MSA | 7 | Qualitative |
| Tatsumi et al., | T2 (1.5T) | Iron: Perls | Brain (fixed) | Microbleeds | 1 | Qualitative |
| van Rooden et al., | T2* (7T) | Iron: Perls + DAB | 10-mm coronal slices of brains (fixed) | AD | 6 | Qualitative |
| Matsusue et al., | T2 (1.5T) | Ferritin: IHC | Cerebellum (fixed) | MSA | 7 | Qualitative |
| Yao et al., | R2* (1.5,3,7T) | Iron: ICP-MS | Brains (fixed) | Control | 2 | Quantitative |
| Fukunaga et al., | R2* (7T) | Iron: Perls + DABFerritin: IHC | Parietal cortex (fixed) | Control | 1 | Qualitative |
| Hopp et al., | SWI (1.5T) | Iron: XRF | Fixed brains | PD | 1 | Qualitative (SWI) and quantitative (Phase) |
| Langkammer et al., | R2 (3T) | Iron: ICP-MS | Fresh brains | Control | 7 | Quantitative |
| Schrag et al., | SWI (3T) | Iron: Perls + DAB | 10-mm coronal slices of brains/Microbleeds (fixed) | AD + CAA | 4 | Qualitative |
| Bagnato et al., | R2* (7T) | Iron: Perls + DAB; Turnbull + DAB + Ammonium sulfideFerritin: IHC (polyclonal, light chain) | 10-mm coronal slices (fixed) | MS | 2 | Qualitative |
| De Reuck et al., | T2 (7T) | Iron: Perls | Whole brains (fixed) | AD with cerebral bleeds | 20 | Qualitative |
| Antharam et al., | R2 (14.1T) | Iron: XRF | Hippocampus (frozen) | AD | 5 | Quantitative |
| Kwan et al., | R2* (7T) | Iron: Perls + DABFerritin: IHC | Motor cortex (fixed) | ALS | 1 | Qualitative |
| Langkammer et al., | QSM (3T) | Iron: ICP-MS | Whole brains (fresh) | Control | 13 | Quantitative |
| Langkammer, | R2 (3T) | Iron: ICP-MS | Frontal lobe (fresh) | Control | 6 | Quantitative |
| Liem et al., | T2 (7T) | Iron: Perls | 10-mm coronal brain slices (fixed) | CADASIL | 3 | Qualitative |
| Massey et al., | T2 (9.4T) | Iron: Perls | STN (fixed) | Control | 8 | Qualitative |
| Zheng et al., | T2* (3T) | Iron: XRF | 10-mm coronal brain slices (fixed) | Stroke | 3 | Qualitative |
| Blazejewska et al., | T2* (7T) | Iron: Perls | Substantia nigra (fixed) | Parkinson | 1 | Qualitative |
| Foroutan et al., | T2 (21.1T) | Iron: PerlsFerritin: IHC (light chain) | Basal ganglia and midbrain (fixed) | PSP | 6 | Qualitative |
| Walsh et al., | R2 (4.7T) | Iron: Perls | Basal ganglia and MS lesions (fresh) | MS | 3 | Quantitative |
| Zheng et al., | QSM (3T) | Iron: XRF | 5-mm coronal brain slice (fixed) | MS | 1 | Quantitative |
| Meadowcroft et al., | T2* (7T) | Iron: Perls + DAB | 60-μm entorinal cortex slices (fixed) | AD | 5 | Qualitative |
| Stüber et al., | R1 (7T) | Iron: Perls and PIXE | Occipital lobe (fixed) | Control | 3 | Quantitative (PIXE) |
| Tan et al., | QSM (3T) | Iron: ICP-MS | Cavernomas (fixed) | Cavernomas | 4 | Quantitative |
| Birkl et al., | R2' (3T) | Iron: SQUID magnetometry and ICP-MS | Whole brain (fresh) | Control | 5 | Quantitative |
| Sun et al., | QSM (4.7T) | Iron: Perls | Whole brain (fresh) | Control | 2 | Quantitative |
| Wisnieff et al., | R2* (3T) | Iron: Perls and LA-ICP-MS | MS lesions (fixed) | MS | 1 | Quantitative (LA-CP-MS) |
| Dusek et al., | T2* (7T) | Iron: Turnbull + DAB + Ammonium sulfide and AAS | Basal ganglia (fixed) | WilsonControl | 9 6 | Quantitative |
| Lee et al., | T2* (7T) | Iron: Perls | Substantia nigra (fixed) | Control | 2 | Quantitative |
| van Veluw et al., | T2 (7T) | Iron: Perls | 5-10-mm coronal brain slices / Microbleeds (fixed) | CAA | 5 | Qualitative |
| Wallace et al., | R2*
| Iron: Perls + DAB, Turnbull + DAB | Whole brain / Occipital lobe / Transverse temporal gyrus (fixed) | Control | 2 | Quantitative |
| Birkl et al., | R2* (3T) | Ferritin: IHC (light chain) | 10-mm coronal brain slices (fixed) | MS | 3 | Quantitative |
| Dal-Bianco et al., | T2 (7T) | Iron: Turnbull + DAB | MS lesions (fixed) | MS | 4 | Qualitative |
| De Reuck et al., | T2* (7T) | Iron: Perls | Coronal brain slices (fixed) | ALS | 12 | Qualitative |
| Massey et al., | T2 (9.4T) | Iron: Perls | Substantia nigra (fixed) | Control | 10 | Qualitative |
| Matsuda et al., | T1 (7T) | Iron: Perls | Ganglioglioma (fixed) | Ganglioglioma | 1 | Qualitative |
| Wiggermann et al., | QSM (3T) | Iron: Turnbull + ammonium sulfide + DAB | MS lesions (fixed) | MS | 5 | Quantitative |
| Bagnato et al., | R2* (7T) | Iron: Turnbull + DAB + Ammonium sulfide | 10-mm coronal brain slices (fixed) | MS | 7 | Quantitative |
| Bulk et al., | R2* (7T) | Iron: EPR and SQUID | Medium temporal gyrus (fixed) | AD | 1 | Quantitative |
| Bulk et al., | T2* (7T) | Iron: Perls + DAB | Medium frontal gyrus (fixed) | AD | 21 | Quantitative |
| Hametner et al., | R2* (7T) | Iron: Turnbull + ammonium sulfide + DAB and ferrozine assay | Whole brain (fresh) | Control | 6 | Quantitative |
| Kaunzner et al., | QSM (3T) | Iron: Perls + DAB | MS lesions | MS | 7 | Qualitative |
| Lee et al., | T1map | Iron: Perls | Substantia nigra (fixed) | Control | 5 | Quantitative |
AAS, atomic absorption spectrometry; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CAA, cerebral amyloid angiopathy; DAB, diaminobenzidine; EPR, electron paramagnetic resonance; FTLD, frontotemporal lobar degeneration; ICP-AES, inductively coupled plasma atomic emission spectrometry; ICP-MS, inductively coupled plasma mass spectrometry; IHC, immunohistochemistry; LA-ICP-MS, laser ablation ICP-MS; MSA, multiple system atrophy; MS, multiple sclerosis; NA, not available; PD, Parkinson's disease; PIXE, particle induced X-ray emission; PMA, progressive muscular atrophy; PSIR, T1 phase sensitive inversion recovery; PSP, progressive supranuclear palsy; QSM, quantitative susceptibility mapping; SQUID, superconducting quantum interference device magnetometer; STN, subthalamic nucleus; SWI, susceptibility weighted images; TBI, traumatic brain injury; TcR2.
Summary of all combinations of MRI sequences with histological or physical technique.
| T1 or T1 map | Perls | Matsuda et al., |
| T1 PSIR | Perls + DAB | |
| T1 PSIR | Turnbull + DAB | |
| T2 or T2map | Perls | Chen et al., |
| T2 or T2 map | AAS | |
| T2 or T2map | Radio-immune assay kit and peroxidase-antiperoxidase method | Chen et al., |
| T2 or T2 map | IHC: Ferritin | Fujii et al., |
| T2* or T2* map | Perls | Tatsumi et al., |
| T2* or T2* map | Perls + DAB | Dhenain et al., |
| T2* or T2* map | IHC: Ferritin | Foroutan et al., |
| T2* or T2* map | Turnbull + DAB + Ammonium sulfide | Dusek et al., |
| T2* or T2* map | XRF | Zheng et al., |
| T2* or T2* map | AAS | Dusek et al., |
| R1 | Perls | House et al., |
| R1 | ICP-AES | |
| R1 | PIXE | |
| R2 | Perls | |
| R2 | AAS | |
| R2 | ICP-AES | |
| R2 | ICP-MS | |
| R2 | XRF | |
| R2' and TcR2' | ICP-MS | |
| R2' and TcR2' | SQUID | |
| R2* | Perls | |
| R2* | Perls + DAB | Fukunaga et al., |
| R2* | Turnbull + DAB | Wallace et al., |
| R2* | Turnbull + DAB + Ammonium sulfide | Bagnato et al., |
| R2* | Ferritin : IHC | Fukunaga et al., |
| R2* | Ferrozine assay | |
| R2* | ICP-MS and LA-ICP-MS | |
| R2* | PIXE | |
| R2* | XRF | |
| R2* | AAS | |
| R2* | EPR | |
| R2* | SQUID | |
| TcR2* | IHC : Ferritin | |
| SWI | Perls | |
| SWI | Perls + DAB | Schrag et al., |
| SWI | Turnbull + DAB | Dal-Bianco et al., |
| SWI | XRF | Hopp et al., |
| Phase | Perls | |
| Phase | Perls + DAB | Bagnato et al., |
| Phase | Turnbull + DAB + Ammonium sulfide | Bagnato et al., |
| Phase | IHC: Ferritin | Bagnato et al., |
| Phase | ICP-MS | |
| Phase | XRF | |
| QSM | Perls | Stüber et al., |
| QSM | Perls + DAB | Kaunzner et al., |
| QSM | Turnbull + DAB + Ammonium sulfide | |
| QSM | ICP-MS and LA-ICP-MS | |
| QSM | XRF | |
| QSM | Ferrozine assay |
AAS, atomic absorption spectrometry; CAA, cerebral amyloid angiopathy; DAB, diaminobenzidine; EPR, electron paramagnetic resonance; ICP-AES, inductively coupled plasma atomic emission spectrometry; ICP-MS, inductively coupled plasma mass spectrometry; IHC, immunohistochemistry LA-ICP-MS, laser ablation ICP-MS; MSA, multiple system atrophy; PIXE, particle induced X-ray emission; PSIR, T1 phase sensitive inversion recovery; QSM, quantitative susceptibility mapping; SQUID, superconducting quantum interference device magnetometer; SWI, susceptibility weighted images; TcR2.
List of all quantitative studies with corresponding correlation parameters.
| Chen et al., | T2 (1.5T) | 5 | 0 | Iron: AAS | No correlation | |
| House et al., | R2 (4.7T) | 0.6 × 0.3 × 4 | 0 | Iron: AAS | A = 0.098 | |
| House et al., | R1 (1.4T) | NA | 0 | Iron: ICP-AES | R1: | R1: A = 0.0034, B = 0.9 |
| Yao et al., | R2* (1.5,3,7T) | 0.7x0.7x0.7 | NA | Iron: ICP-MS | A = 0.0099 | |
| Langkammer et al., | R2 (3T) | 1 × 1 × 4 | 0 | Iron: ICP-MS | R2: | R2: A = 0.04, B = 8.5 |
| Hopp et al., | Phase (1.5T) | 0.5 × 0.5 × 2 | NA | Iron: XRF | Phase: | Phase: A = 0.0025, B = −0.13 |
| Antharam et al., | R2 (14.1T) | 0.062 × 0.062 × 0.08 | 0 | Iron: XRF | R2: | NA |
| Langkammer, | QSM (3T) | 0.5 × 0.5 × 2 | 0 | Iron: ICP-MS | A = 0.00097, B = −0.037 | |
| Langkammer et al., | R2* (3T) | 0.5 × 0.5 × 2 | 0 | Iron: ICP-MS | R2*: | R2*: A = 0.12, B = 22.38 |
| Walsh et al., | T2 (4.7T) | 0.25 × 0.25 × 1–2 | 0 | Iron: Perls | T2: | NA |
| 0 h 08 min 54 s | ||||||
| Zheng et al., | QSM (3T) | 0.5 × 0.5 × 0.7 | 6 hours | Iron: XRF | A = 0.79-0.80,B = −3.66-+10.81 | |
| Stüber et al., | R1 (7T) | 0.2 × 0.2 × 0.2 | 30 days | Iron: PIXE | R1 | A = 0.249 |
| Tan et al., | QSM (3T) | NA × NA × 0.4 | NA | Iron: ICP-MS | NA | |
| Birkl et al., | R2' (3T) | 1 × 1 × 2 | 0 | Iron: ICP-MS | R2': | A = 0.11, B = 8.85 |
| Sun et al., | QSM (4.7T) | 0.8–1 × 1 × 2 | 0 | Iron: Perls | NA | |
| Wisnieff et al., | R2* (3T) | 0.7 × 0.7 × 0.7 | NA | Iron: LA-ICP-MS | NA | NA |
| Dusek et al., | R2* (7T) | 0.5 × 0.5 × 2 | NA | Iron:Turnbull + DAB + ammonium sulfide and AAS | Turnbull: | NA |
| Lee et al., | T2* (7T) | 0.136 × 0.136 × 0.5 | 3-5 months | Iron: Perls | A = −8.05-−12.64 | |
| Wallace et al., | PSIR | 0.3 × 0.3 × 0.6 | Several months | Iron: Perls + DAB and Turnbull + DAB | NA | |
| Birkl et al., | R2* (3T) TcR2* (3T) | 0.5 × 0.5 × 2 | NA | Ferritin: IHC (light chain) | R2*: | A = 0.06, B = 37.51 |
| 6 | ||||||
| Wiggermann et al., | QSM (3T) | 0.4 × 0.4 × 0.8 | NA | Iron: Turnbull + ammonium sulfide + DAB | NA | |
| Bagnato et al., | R2* (7T) | 0.7 × 0.7 × 0.7 | Several years | Iron: Turnbull + DAB+ ammonium sulfide | NA | |
| Bulk et al., | R2* (7T) | × 0.1 × 0.1 3 h 30 min 0 s | 4 weeks – 3 years | Iron: EPR and SQUID | ρ = 0.12 | NA |
| Bulk et al., | T2* (7T) | / | NA | Iron: Perls + DAB | NA | |
| Lee et al., | T1map (7T) | 0.136 × 0.136 × 0.5 | NA | Iron: Perls | T1map: | NA |
| Hametner et al., | R2* (7T) | 0.43 × 0.43 × 0.65 | 0 | Iron: Turnbull + ammonium sulfide + DAB | Turnbull: R2*: | A = 0.51236, B = 15.2827 |
AAS, atomic absorption spectrometry; CAA, cerebral amyloid angiopathy; DAB, diaminobenzidine; EPR, electron paramagnetic resonance; ICP-AES, inductively coupled plasma atomic emission spectrometry; ICP-MS, inductively coupled plasma mass spectrometry; IHC, immunohistochemistry; LA-ICP-MS, laser ablation ICP-MS; MSA, multiple system atrophy; NA, not available; PIXE, particle induced X-ray emission; PSIR, T1 phase sensitive inversion recovery; QSM, quantitative susceptibility mapping; SQUID, superconducting quantum interference device magnetometer; SWI, susceptibility weighted images;TcR2.
XxY, in-plane resolution; Z, thick section
iron correlated with R2*/tesla rather than R2*
linear equation parameters determined with myelin inference
correlation with iron expressed in kg/mg dry weight determined by PIXE
linear equation parameters determined with neuromelanin inference
Spearman correlation coefficient.
Technical description of Perls' and Turnbull staining with brief description of correlation methodology with MRI.
| Chen et al., | Not described | No | / | No | Visual |
| Dhenain et al., | 30 min 2% PF 2% HCL | Yes | 7 μm | Yes | Visual |
| Fujii et al., | Not described | No | / | No | Visual |
| House et al., | 1 h 7% PF 3% HCL 37 °C | No | 6 μm | Yes | Visual |
| Tatsumi et al., | Not described | No | / | No | Visual |
| Matsusue et al., | Not described | No | / | No | Visual |
| van Rooden et al., | 15 h 7% PF 3% HCL | Yes | 5 μm | No | Visual |
| Schrag et al., | 20 min 10% PF 20% HCL | Yes | 8 μm | No | Visual |
| Fukunaga et al., | 2 h 5%PF 5% HCL 37 C | Yes | 20 μm | No | Visual |
| Bagnato et al., | 15 min 1% PF 1% HCL | Yes | 3-7 μm | Yes | Visual |
| De Reuck et al., | Not described | No | 12 μm | No | Visual |
| Massey et al., | Not described | No | 20 μm | Yes | Visual |
| Kwan et al., | 1 h 2% PF 2% HCL | Yes | 6 μm | No | Visual |
| Liem et al., | Not described | No | 10 μm | No | Visual |
| Blazejewska et al., | Not described | No | 5 μm | Yes | Visual after coregistration |
| Foroutan et al., | Time not given 10% PF 20% HCL | No | 5 μm | Yes | ROI to ROI |
| Walsh et al., | 30 min 1% PF 1% HCL | No | 8mm | Yes | ROI to ROI with optical density |
| Meadowcroft et al., | 30 min 2% PF 2% HCL | Yes | 60 μm | Yes | Visual |
| Stüber et al., | Not described | No | 30 μm | No | Visual |
| Sun et al., | 30 min 1% PF 1% HCL | No | 8mm | Yes | ROI to ROI with optical density |
| Wisnieff et al., | 1.5 h 5% PF 10% HCL then microwaved | No | 10 μm | Yes | Visual after coregistration |
| Lee et al., | Time not given 20% PF 20% HCL | No | 50 μm | Yes | Voxelwise correlation analyses after coregistration |
| van Veluw et al., | Not described | No | 6 μm | No | Visual |
| Wallace et al., | 2H 50% PF 2.5%HCL 37°C | Yes | 40 μm | Yes | Mean intensity in ROI after coregistration |
| De Reuck et al., | Not described | No | / | No | Visual |
| Massey et al., | Not described | No | 20 μm | No | Visual |
| Matsuda et al., | Not described | No | 6 μm | Yes | Visual after coregistration |
| Bulk et al., | 30 min 1% PF HCL for pH <5.5 | Yes | 20 μm | Yes | Pixel-based spatial correlation after coregistration |
| Kaunzner et al., | 30 min 4% PF 4% HCL | Yes | 5 μm | Yes | Visual |
| Lee et al., | Time not given 20% PF 20% HCL | No | 50 μm | Yes | Voxelwise correlation analyses after coregistration |
| Bagnato et al., | 90 min AS then 15 min 10% Pf 0.5% HCL | Yes | 3-7 μm | Yes | Visual |
| Dusek et al., | 90 min AS then 15 min 10% Pf 0.5% HCL | Yes | 5 μm | Yes | Area fraction in ROI after coregistration |
| Wallace et al., | 2 h 50% Pf 2.5% HCL 37 °C | Yes | 40 μm | Yes | Mean intensity in ROI after coregistration |
| Wiggermann et al., | 90 min AS then 15 min 10% Pf 0.5% HCL | Yes | 10 μm | Yes | Area fraction and mean intensity in ROI after coregistration |
| Bagnato et al., | 90 min AS then 15 min 10% Pf 0.5% HCL | Yes | 10 μm | Yes | Mean intensity in ROI after coregistration |
| Hametner et al., | 90 min AS then 15 min 10% Pf 0.5% HCL | Yes | 10 μm | Yes | Mean intensity in ROI without coregistration |
AS, Ammonium sulfide, HCL, hydrochloric acid; PF, potassium ferrocyanide; Pf, potassium ferricyanide; ROI, region of interest. when reaction temperature not given, assume room temperature. Solid line separates Perls' procedures (above) from Turnbull procedures (below).
Figure 3Ex vivo MRI. T1-weighted sequence. Black arrows depict light band of formalin-fixed tissue. Image obtained during experimental procedures with all appropriate ethical approval. Included for illustrative purposes.
Figure 4Example of artifacts. Perls + DAB: yellow arrow = tears; black arrow = vascular dilation; blue arrow = paravascular dilation; red arrow = knife mark (a). Phase image: black arrow = vascular blood clot (b). R2* image: white arrows = trapped air bubbles; blue arrow = paravascular dilation (c). Image obtained during experimental procedures with all appropriate ethical approval. Included for illustrative purposes.
Key points to consider in histology, ex vivo MRI, iron-based sequences and image coregistration, in order to limit methodological problems and to compare studies.
| Time between death and MRI (fresh) | Spatial resolution | Slice thickness | Image file formats |
| Time between death and fixation (fixed) | Slice thickness | Staining protocol | Up- or downsampling image resolution |
| Fixation period before MRI | Acquisition time | Type of staining | Non-linear transformation? |
| Fixative agent | NSA | Fixation time between MRI and histology | Stack procedure? |
| Degree of putrefaction | Number of echoes (relaxometry) | Tears | Color deconvolution? |
| Imaging solution | Echo time (relaxometry) | Stretching | Thresholded out background |
| Rehydration or not (fixed) | Post-processing algorithms (QSM) | Shrinkage | Grayscale conversion |
| Rehydration time (fixed) | Distortions | ||
| Room temperature | Swelling | ||
| Air/tissue interface (bubbles) | Blood vessel or paravascular space dilation | ||
| Contention technique to avoid vibrations | Knife mark | ||
| Specimen orientation | Sampling | ||
| RF coil type | |||
| Intravascular blood clot or paravascular space dilation |
NSA, number of signals averaged; QSM, quantitative susceptibility mapping; RF, radiofrequency; ROI, region of interest.